EpiCast Report: Atrial Fibrillation – Epidemiology Forecast to 2025

Date: 2016-08

EpiCast Report: Atrial Fibrillation – Epidemiology Forecast to 2025


Atrial fibrillation (AF) is a disorder of the heart鈥檚 conduction system. The condition is characterized by an irregular heart rhythm that is either too fast or too slow. During AF, the two upper chambers of the heart (atria) beat out of coordination with the two lower chambers (ventricles) due to disorganized electrical signals. Consequently, the blood doesn鈥檛 flow as well as it should from the atria to the ventricles, resulting in poor blood supply to the rest of the body. AF symptoms typically include heart palpitations, chest discomfort, shortness of breath, dizziness, and weakness (CDC, 2015; Mayo Clinic, 2016; NHLBI, 2014). However, individuals with AF may be asymptomatic and not even know that they have the condition until it is identified through an electrocardiogram (ECG) test.

In the 8MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of AF will increase from 9,487,217 cases in 2015 to 11,536,773 cases in 2025, at an Annual Growth Rate (AGR) of 2.16%. The US will have the highest number of diagnosed prevalent cases of AF among the 8MM throughout the forecast period, while Canada will have the lowest. In the 8MM, permanent AF is forecast to be the predominant subtype of AF. In the US, Germany, Spain, the UK, Japan, and Canada, paroxysmal AF is forecast to be the second most predominant subtype, while persistent AF is the second most common subtype in France and Italy.


– The Atrial fibrillation (AF) EpiCast Report is an overview of the risk factors, comorbidities, and the global and historical trends for AF in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AF based on country-specific studies published in peer-reviewed journals. The diagnosed prevalent cases of AF are segmented by age (at 5-year intervals, starting at age 40 years), sex, and clinical subtypes (paroxysmal, persistent, and permanent AF) in the 8MM.
– The AF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The AF EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global AF market.
– Quantify patient populations in the global AF market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AF therapeutics in each of the markets covered.



Contact With Us
Join templatemonster at google+
Customized Research
Request Sample